(Q46508940)

English

Novel agents in cystic fibrosis

scientific article published in July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

Novel agents in cystic fibrosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

cystic fibrosis

0 references

author name string

Shane Storey

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

Graeme Wald

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

publication date

1 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

555-556

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

https://scigraph.springernature.com/pub.10.1038/nrd2603

0 references

Restoring airway surface liquid in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2603

31 March 2020

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD2603

31 March 2020

Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNRD2603

31 March 2020

Inhalation of Moli1901 in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2603

31 March 2020

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L

1 reference

https://api.crossref.org/works/10.1038%2FNRD2603

31 March 2020

Identifiers

10.1038/NRD2603

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18591977

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46508940&oldid=2115327993"